Cyclic Peptide Technology Enables Oral Insulin Delivery That Actually Works in Diabetic Mice
A small intestine-permeable cyclic peptide carrier enables oral delivery of zinc-stabilized insulin hexamers in diabetic mice, achieving rapid and sustained blood sugar reduction.
Quick Facts
What This Study Found
DNP-V cyclic peptide carrier enables efficient oral delivery of zinc-stabilized insulin hexamers with rapid, robust, and sustained glycemic efficacy in diabetic mice.
Key Numbers
How They Did This
Peptide engineering of DNP-V carrier; co-administration with zinc-stabilized insulin hexamers; oral dosing in diabetic mouse models; blood glucose monitoring.
Why This Research Matters
If oral insulin works in humans, it would eliminate billions of daily injections worldwide and dramatically improve diabetes management adherence and quality of life.
The Bigger Picture
This represents a breakthrough in oral protein delivery — using peptide carriers to ferry large therapeutic proteins across the intestinal barrier, potentially applicable to many injectable drugs beyond insulin.
What This Study Doesn't Tell Us
Mouse model — human intestinal permeability differs significantly; scale-up of peptide carrier manufacturing; bioavailability and dose-response in humans unknown.
Questions This Raises
- ?What is the oral bioavailability of insulin delivered with DNP-V in larger animal models?
- ?Could this platform deliver other injectable peptide drugs like GLP-1 agonists orally?
Trust & Context
- Key Stat:
- Oral insulin works in mice DNP-V peptide carrier enables intestinal insulin absorption with sustained glycemic effect
- Evidence Grade:
- Preclinical mouse study — promising proof of concept but many oral insulin candidates have failed in human translation.
- Study Age:
- Published in 2026, representing the latest advance in the long quest for oral insulin delivery.
- Original Title:
- Small Intestine-Permeable Cyclic Peptide-Based Technology Enables Efficient Oral Delivery and Glycemic Efficacy of Zinc-Stabilized Insulin Hexamer and Its Analogs in Diabetic Mice.
- Published In:
- Molecular pharmaceutics, 23(1), 252-264 (2026)
- Authors:
- Chikamatsu, Shoma, Sakaguchi, Kosei, Michigami, Masataka(2), Araki, Kimi, Kume, Shoen, Tokuyasu, Midori, Masuda, Takeshi, Fujii, Ikuo, Ohtsuki, Sumio, Ito, Shingo
- Database ID:
- RPEP-15030
Evidence Hierarchy
Frequently Asked Questions
Could this mean insulin pills instead of injections?
In mice, this technology enabled oral insulin that effectively lowered blood sugar. If it translates to humans, it could replace daily insulin injections with pills — but many technical challenges remain.
Why has oral insulin been so difficult to develop?
Insulin is a protein that gets destroyed by stomach acid and digestive enzymes, and even if it survives, it's too large to cross the intestinal wall. This cyclic peptide carrier solves both problems by protecting insulin and shuttling it across the intestinal barrier.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15030APA
Chikamatsu, Shoma; Sakaguchi, Kosei; Michigami, Masataka; Araki, Kimi; Kume, Shoen; Tokuyasu, Midori; Masuda, Takeshi; Fujii, Ikuo; Ohtsuki, Sumio; Ito, Shingo. (2026). Small Intestine-Permeable Cyclic Peptide-Based Technology Enables Efficient Oral Delivery and Glycemic Efficacy of Zinc-Stabilized Insulin Hexamer and Its Analogs in Diabetic Mice.. Molecular pharmaceutics, 23(1), 252-264. https://doi.org/10.1021/acs.molpharmaceut.5c00902
MLA
Chikamatsu, Shoma, et al. "Small Intestine-Permeable Cyclic Peptide-Based Technology Enables Efficient Oral Delivery and Glycemic Efficacy of Zinc-Stabilized Insulin Hexamer and Its Analogs in Diabetic Mice.." Molecular pharmaceutics, 2026. https://doi.org/10.1021/acs.molpharmaceut.5c00902
RethinkPeptides
RethinkPeptides Research Database. "Small Intestine-Permeable Cyclic Peptide-Based Technology En..." RPEP-15030. Retrieved from https://rethinkpeptides.com/research/chikamatsu-2026-small-intestinepermeable-cyclic-peptidebased
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.